- Previous Close
14.82 - Open
14.94 - Bid 14.07 x 100
- Ask 14.21 x 100
- Day's Range
12.92 - 14.94 - 52 Week Range
12.51 - 23.36 - Volume
2,259,501 - Avg. Volume
1,454,260 - Market Cap (intraday)
438.103M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-87.00 - Earnings Date Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
grail.com1,360
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GRAL
View More
Performance Overview: GRAL
Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRAL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRAL
View MoreValuation Measures
Market Cap
437.95M
Enterprise Value
-444.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.99
Price/Book (mrq)
0.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
109.74M
Net Income Avi to Common (ttm)
-2.88B
Diluted EPS (ttm)
-87.00
Balance Sheet and Cash Flow
Total Cash (mrq)
958.84M
Total Debt/Equity (mrq)
2.82%
Levered Free Cash Flow (ttm)
--
Company Insights: GRAL
GRAL does not have Company Insights